KTL Advanced Biomaterial Commercialization Support Program Guide 2026

Overview of the Advanced Biomaterial Commercialization Support Program

The Advanced Biomaterial Commercialization Support Program, organized by the Korea Testing Laboratory (KTL), is a flagship initiative aligned with the Ministry of Trade, Industry and Energy's Bioeconomy 2030 strategy. It aims to strengthen the global competitiveness of Korean SMEs in the biomaterial sector. In 2026, the program's budget has been expanded by approximately 25% to KRW 28 billion, supporting an estimated 80 to 100 companies with tailored, stage-specific assistance.

Policy Background and Direction

The global biomaterial market is projected to grow from USD 470 billion in 2025 to USD 780 billion by 2030, an annual growth rate of 10.7%. However, Korea's self-sufficiency rate in core biomaterials remains around 30%. The government has set 50% localization and KRW 1 trillion in import substitution as core targets for 2026.

Support Scope and Full Commercialization Pipeline

KTL focuses on companies at the pre-commercialization stage, distinguishing this program from traditional R&D initiatives.

Stage-by-Stage Support

Prototype Development: Pilot line access and up to KRW 150 million for 1–3 prototype iterations

Quality Evaluation and Testing: Free property, safety, and efficacy testing using KTL's infrastructure

Standardization and Certification: ISO 10993 (biocompatibility), ISO 13485, CE-MDR, FDA 510(k) certification consulting

Market Entry: Global buyer matching, up to KRW 30 million for international trade show participation, post-contract export support

Funding Scale

Each selected company receives an average integrated support package of KRW 300–500 million, with 70% government funding and 30% company contribution (10% cash + 20% in-kind).

Application Schedule and Eligibility

2026 Timeline

First Call: Mid-March 2026 (30-day application window)

Second Call: Early July 2026 (30-day application window)

Evaluation and Agreement: Within 60 days after application deadline

Project Duration: 12 months from contract date (extendable up to 24 months)

Eligibility Requirements

Domestic SMEs or mid-sized enterprises (preference for startups under 7 years)

At least one registered or pending patent related to biomaterials

R&D expenditure of 3% or more of revenue in the last 3 years

Debt-to-equity ratio under 500%, credit rating BB- or above

Priority Sectors

Novel Biomaterials: Biodegradable plastics, biopolymers, natural extract materials

Medical Materials: Artificial organ materials, drug delivery systems (DDS), tissue engineering scaffolds

Eco-Friendly Biomaterials: Microbial-based chemicals, enzymatic materials, green bio chemicals

Key Points for Business Plan Writing

Evaluation criteria allocate 35 points to technology, 30 to market viability, 25 to commercialization strategy, and 10 to corporate capability. Market viability and commercialization strategy carry significant weight, requiring a different approach from pure R&D proposals.

Core Writing Strategies

Technology: Quantify advantages over existing materials (e.g., 20%+ performance gain, 30% cost reduction)

Market Viability: TAM-SAM-SOM analysis, 3-year revenue targets, attached Letters of Intent (LOIs) from key customers

Commercialization Strategy: Mass production roadmap, certification timeline, country-specific export plans

Bonus Point Strategy

Up to 10 bonus points are available through patents (2 pts domestic / 3 pts PCT), existing certifications (2 pts ISO), export records (2 pts), female/youth CEOs (1 pt), and regional companies (2 pts).

How KITIM Consulting Can Help

KITIM is a specialized consulting firm with a 75%+ selection rate for KTL commercialization programs. We go beyond proposal writing, delivering an integrated roadmap aligned with KTL's testing and certification schedule.

KITIM Services

Pre-Eligibility Diagnosis: Free 30-minute consultation to evaluate selection probability

Proposal Writing Support: 1:1 advisory by former evaluators with 3 rounds of revisions

Presentation Coaching: 2 mock presentations and 100 Q&A drills

Certification Roadmap: Integrated timeline management for ISO 13485, CE, FDA, and other global certifications

Post-Contract Management: Stage-based reporting and settlement support after agreement signing

Don't miss this pivotal opportunity in biomaterial commercialization. Partner with KITIM's expert consultants to win selection in the KTL Advanced Biomaterial Commercialization Program and accelerate your global market entry. Request your free consultation today for a customized strategic proposal.